Who is sponsoring NCT05468242?

NCT05468242 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05468242?

Interventions in NCT05468242: Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab.

What condition does NCT05468242 study?

NCT05468242 studies Stage III Non-small Cell Lung Cancer.

Is NCT05468242 still recruiting?

NCT05468242 is currently recruiting now. Last updated 30 October 2024.

Last reviewed 2024-10-30 · How we verify

NCT05468242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Recruiting now Phase 2 Last updated 30 October 2024

What this trial tests

Phase 2 trial testing Neoadjuvant chemo-immunotherapy in Stage III Non-small Cell Lung Cancer in 116 participants. Currently enrolling.

Timeline

1 January 2022

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	116
Start date	1 January 2022
Primary completion	30 December 2024
Estimated completion	30 December 2024
Sites	1 location across China

Drugs / interventions tested

Neoadjuvant chemo-immunotherapy — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Radiotherapy — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →

Conditions studied

Stage III Non-small Cell Lung Cancer — all drugs for Stage III Non-small Cell Lung Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Stage III Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1
Oligometastatic NSCLC: Current Perspectives and Future Challenges.
Torresan S, Costa J, Zanchetta C, De Marchi L, et al · · 2025 · cited 6× · PMID 39996875 · DOI 10.3390/curroncol32020075
Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment.
Yuan M, Zhai Y, Hui Z. · · 2022 · cited 4× · PMID 36439496 · DOI 10.3389/fonc.2022.978608
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.
Burcher K, Karukonda P, Kelsey C, Mullikin T, et al · · 2025 · cited 3× · PMID 40507315 · DOI 10.3390/cancers17111829
Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: implications for immunotherapy.
Hang ZS, Huang YY, Song A, Sun ZJ. · · 2025 · cited 1× · PMID 40765564 · DOI 10.7150/ijms.109515

Verify or expand the search:

Other trials of Neoadjuvant chemo-immunotherapy

Trials testing the same drug.

NCT07092449 — Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcin · NA · not yet recruiting

Other recruiting trials for Stage III Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05468242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 30 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05468242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing